Sponsors (5)
The bill directs DoD to study and coordinate potential access to psilocybin therapy for servicemembers and veterans—potentially expanding treatment options and establishing oversight—while raising substantial concerns about unknown clinical risks, operational readiness impacts, legal/liability questions, privacy, and additional costs.
Servicemembers and veterans with treatment-resistant PTSD: creates a formally explored pathway for potential access to psilocybin-based therapy, offering a possible new clinical option when other treatments have failed.
Military health systems and hospitals: requires collection and reporting of safety, dosing, and adverse-event data to inform safer clinical use and oversight for any future psilocybin treatment programs.
Servicemembers transitioning to civilian care and VA providers: assesses continuity of care between DoD and VA, which could improve transition-period treatment, follow-up, and reporting for investigational therapies.
Servicemembers and veterans: exposes participants to unknown clinical risks and adverse events from an investigational Schedule I drug that lacks full FDA approval.
Deployed or high-readiness military units and their commanders: potential acute side effects or monitoring needs could reduce medical readiness and operational effectiveness.
Servicemembers and veterans: relying on Right to Try or executive-order pathways risks circumventing full FDA approval and creates legal, liability, and ethical questions for patients and departments.
Based on analysis of 2 sections of legislative text.
Requires DoD to report within 180 days assessing a 2026 psilocybin PTSD trial for service member safety, legality, continuity of care, and implementation needs for pilot activities.
Official title: To direct the Secretary of Defense to submit to Congress a report on emerging investigational treatment options for treatment-resistant post-traumatic stress disorder in veterans, members of the Armed Forces, and members transitioning to civilian life, and for other purposes.
Introduced June 30, 2026 by Abraham J. Hamadeh · Last progress June 30, 2026
Requires the Department of Defense to produce a report within 180 days evaluating results from a 2026 clinical trial of whole‑mushroom psilocybin for PTSD and how that evidence might apply to active duty members. The report must cover safety, dosing, adverse events, operational and readiness implications, legal/regulatory pathways for investigational Schedule I use, transition and continuity of care with VA, and estimated costs, workforce, infrastructure needs, and a timeline for pilot activities starting FY2027. The report is to be prepared with the Defense Health Agency and in consultation with VA, HHS, FDA, and other agencies; it must be submitted unclassified with an optional classified annex and should assess use under Federal Right to Try and applicable executive guidance.